Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
10.73
+1.21 (12.71%)
At close: Jun 26, 2026, 4:00 PM EDT
10.90
+0.17 (1.58%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Akari Therapeutics, Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Akari Therapeutics, stock have an average target of 33.5, with a low estimate of 27 and a high estimate of 40. The average target predicts an increase of 212.21% from the current stock price of 10.73.
Analyst Consensus: Buy
* Price targets were last updated on Apr 21, 2026.
Analyst Ratings
The average analyst rating for Akari Therapeutics, stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $27 | Buy | Reiterates | $27 | +151.63% | Apr 21, 2026 |
| Maxim Group | Maxim Group | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Apr 8, 2026 |
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Initiates $40 | Buy | Initiates | $40 | +272.79% | Jan 5, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-12.00
EPS Next Year
-14.00
from -12.00
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -12.00 | -14.00 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.